The week ahead – week 19

  • The American Society of Gene & Cell Therapy has an Annual Meeting in Washington D.C.
  • The American Urological Association also has its Annual Meeting in Boston.
  • AbbVie presents induction data from a Phase II trial upadacitinib trial and risankizumab data from a Phase II trial, both in Crohn’s disease at DWW.
  • pSivida  presents 20-week Duraset data from a Phase II study in posterior segment uveitis at ARVO.
  • Pfizer presents data from its Xeljanz OCTAVE Sustain Phase III study in ulcerative colitis at DDW.
  • Synergy Pharma presents Trulance data from two Phase III trials in constipation-predominant irritable bowel syndrome at DDW.
  • Synthetic Biologics presents data from a ribaxamase Phase IIb trial in Clostridium difficile infections.
  • Merck has a PDUFA date of Keytruda sBLA in combination with Alimta and carboplatin in first-line non-squamous non-small cell lung cancer regardless of PD-L1 expression.